Overview of Volmax

Property	Description
Active ingredient	Salbutamol (or Albuterol)
Form	Extended-release oral tablet
Pharmacological class	Selective beta2-adrenergic agonist
General purpose	To induce bronchodilation (airway opening)
Origin	Synthetic compound

Volmax: Defining the Type of Medicine and its Composition

Volmax is a pharmaceutical preparation that contains the active ingredient Salbutamol, which is classified pharmacologically as a selective beta2-adrenergic agonist. This classification places it within the family of bronchodilators, a group clinically recognized for their ability to provide relief from respiratory constriction. The active compound, also known as Albuterol in the United States, is a synthetic compound specifically engineered to interact with certain receptors in the body. Selective beta2-agonists are standard agents used to relax the muscles of the airways. Volmax is a prescription-only medicine (POM) and a single-ingredient product, delivering only the necessary therapeutic compound.

What Makes Volmax Different from Other Salbutamol Forms?

The most differentiating feature of the Volmax brand is its physical form: an extended-release oral tablet designed for systemic administration through swallowing. Unlike the rapid, acute relief focus of most Salbutamol inhalers, this oral preparation utilizes a unique sustained-release delivery system. This sophisticated design ensures that the Salbutamol sulfate is slowly and predictably released from the tablet matrix over an extended duration. This approach to controlled-release dosage forms prioritizes a stable, steady presence of the active ingredient in the body, providing prolonged systemic bronchodilator support.

General Purpose of Volmax: Function and Benefit

The general purpose of Volmax is to act as a bronchodilator by achieving the essential physiological effect of bronchial smooth muscle relaxation. By stimulating specific receptor sites, the medication relieves the involuntary tightening of the air passages in the lungs. This action, known as bronchodilation, helps to open constricted airways. The main benefit of this continuous, systemic function is to assist in maintaining a sustained ease of airflow, which is typically desired by adult patients managing chronic conditions characterized by airway constriction.

Regulatory References

selective \beta2-agonists are standard agents used to relax the muscles of the airways

What side effects are possible with Volmax?

Possible Side Effects and Safety Information

The officially documented adverse effects for Volmax (Salbutamol/Albuterol extended-release oral tablets) are classified based on the frequency observed in clinical data and post-marketing reports, reflecting the drug's systemic profile as a beta2-adrenergic agonist.

Adverse reactions are grouped by System-Organ Class (SOC) and can involve several bodily systems, particularly the nervous, cardiac, and musculoskeletal systems.

Frequency-Classified Adverse Reactions

Regulatory documents classify the following effects based on incidence:

Very Common (geq10%): Tremor and Headache.
Common (1% to <10%): Nervousness, Palpitations, Tachycardia (increased heart rate), Insomnia, Dizziness, Muscle Cramps, Nausea, and Vomiting.

Some of these undesirable effects are characteristic of sympathomimetic agents and are noted in official labeling as potentially subsiding with continued use of the medicine.

Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but clinically significant events that warrant attention. These include the potential for Paradoxical Bronchospasm, which is explicitly noted as a severe reaction, and Immediate Hypersensitivity Reactions (e.g., angioedema, anaphylaxis). Reports of Myocardial Ischemia (reduced blood flow to the heart muscle) have also been received in post-marketing data.

The medicine is subject to safety constraints for specific populations. Caution is required for patients with pre-existing conditions such as cardiovascular disorders (coronary insufficiency, hypertension), diabetes mellitus, and hyperthyroidism. The use of beta2-agonists may also lead to Hypokalemia (low potassium levels) and can cause transient metabolic changes like increased blood glucose, which is a consideration for diabetic patients.

Overdose and Emergency Response

Volmax Overdose and When to Seek Help

Overdosage of Volmax (albuterol/salbutamol extended-release) is primarily characterized by the exaggeration of documented pharmacological effects due to excessive beta-adrenergic stimulation. The official overdose profile, based on regulatory documents, dictates the required response and monitoring.

Documented Overdose Manifestations

Excessive exposure may present with symptoms such as tachycardia (rapid heart rate), tremor, headache, and nervousness. More serious outcomes include potentially life-threatening cardiac arrhythmias and severe hypokalemia (low serum potassium levels) and metabolic acidosis.

Required Emergency Actions

Urgent medical attention must be sought immediately for any suspected or confirmed overdose. Official guidelines require the discontinuation of Volmax and the initiation of appropriate supportive and symptomatic treatment in a monitored setting.

Regulatory information specifies that management may involve continuous monitoring of serum potassium levels and ECG (cardiac function) to detect critical disturbances. A cardioselective beta-blocking agent may be considered to manage severe cardiovascular effects, though this must be done with caution. Treatment remains supportive and is guided by the specific clinical and metabolic findings observed.

Therapeutic Uses of Volmax

The primary use of Volmax (extended-release Salbutamol/Albuterol oral tablets) is in managing symptoms for patients with chronic obstructive airway diseases. The medication is generally used to help with symptoms caused by conditions where airways narrow, making breathing more difficult.

Therapeutic Focus and Patient Benefit

Volmax is commonly used as a maintenance treatment for conditions characterized by periods of heightened symptoms, such as Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD). It is applied across therapeutic domains where additional symptomatic support is needed, addressing the cluster of symptoms related to heightened physiological activity, including chronic wheezing, sensations of chest tightness, and persistent shortness of breath (dyspnea). This sustained action may assist with maintaining stability when symptoms interfere with routine activities and contributes to easing the overall symptom load.

The sustained-release formulation is considered relevant when symptoms become more disruptive during flare-ups or worsen overnight. Applied in scenarios where additional management of discomfort is required, the medication provides continuous support to help address symptom clusters that interfere with daily comfort. This may assist in maintaining a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes of nocturnal distress. It is generally considered relevant for long-term symptom management in adult patients, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Airflow Obstruction Symptoms

Regulatory References

MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Volmax?

Volmax (salbutamol extended-release oral tablet) eligibility is defined by strict regulatory criteria based on age, pre-existing conditions, and patient sensitivity.

Absolute Prohibitions

The medicine is strictly contraindicated for patients with a known history of hypersensitivity to albuterol or any tablet components. Use is also formally contraindicated in all children 6 years of age and younger as this specific oral formulation is not intended for this age group. Furthermore, non-intravenous formulations of salbutamol are prohibited for use as a tocolytic agent for threatened abortion or to arrest uncomplicated premature labour.

Restricted Populations and Conditions

Use requires explicit caution in populations with specific pre-existing conditions, including cardiac arrhythmias, hypertension, coronary insufficiency, hyperthyroidism, diabetes mellitus, and seizure disorders. Older adults (geriatric patients) are eligible but require caution and may necessitate an initial lower dosage. The medicine is classified as Pregnancy Category C, and regulatory documents note insufficient data to fully assess risk when used by breastfeeding individuals.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Volmax (extended-release Salbutamol/Albuterol oral tablet) is structured around preventing antagonistic effects and managing the potentiation of cardiovascular and metabolic risks, as documented in regulatory information.

Documented Pharmacodynamic and Exposure Interactions

Interacting Substance Category	Official Interaction Outcome and Constraint
Non-selective Beta-Blockers (e.g., Propranolol)	Pharmacodynamic antagonism; the combination should not usually be prescribed due to the risk of severe bronchospasm.
Diuretics, Corticosteroids, Xanthine Derivatives	Risk of exacerbated hypokalemia (low potassium); co-administration requires careful evaluation.
Monoamine Oxidase Inhibitors (MAOIs) / Tricyclic Antidepressants (TCAs)	Potential for vascular system potentiation; administer with extreme caution or avoid use within two weeks of discontinuation.
Digoxin	Volmax is documented to reduce serum Digoxin concentrations by 16% to 22%, requiring monitoring of Digoxin levels.
Halogenated Anaesthetics	Timing separation is required; treatment should be discontinued, whenever possible, at least 6 hours before scheduled anaesthesia due to risk of ventricular rhythm disorders.

Other Restrictions

Concomitant use with other oral sympathomimetic agents is not recommended due to the potential for deleterious cardiovascular effects. No mandatory interaction rules are uniformly documented across major labels regarding administration with food, alcohol, or herbal products.

Mechanism of Action

How Volmax Works

Volmax is a selective inhibitor of the enzyme XYZ-Kinase (XYK). This molecular interaction decreases the phosphorylation rate of downstream substrates regulated by XYK.

Modulation of the XYK pathway alters the functional state of specific cell-to-cell signaling components. The inhibition prevents the subsequent activation of the PQR-Factor and reduces its nuclear translocation, thereby altering the transcription of regulatory proteins involved in cellular processes. This mechanistic cascade affects the signaling elements that govern cellular homeostasis.

Functionally, the biochemical consequence is a measurable decrease in the synthesis of Inflammatory Mediator Z within the targeted tissue. This pharmacodynamic effect represents the final system-level modulation achieved through the specific inhibition of XYK.

Dosage and Administration Information

Volmax (albuterol extended-release tablets) is a prescription medication used to manage bronchospasm in adults and children aged 6 years and older with reversible obstructive airway disease, such as asthma or chronic obstructive pulmonary disease (COPD).

Administration Guidelines

Volmax must be taken exactly as prescribed by your healthcare provider. The dosing schedule for extended-release tablets is typically every 12 hours, ideally at the same times each day to maintain steady therapeutic levels. Do not take more or less than the prescribed dose, or take it more often than directed.

Action	Instruction
Swallowing	Swallow the tablet whole with water or another liquid.
Tablet Integrity	Do not cut, crush, or chew the extended-release tablet. This action can cause the medication to be released too quickly, potentially increasing side effects and reducing its effectiveness.
With Food	Volmax may be taken with or without food. If the medication causes stomach upset, taking it with food may help alleviate symptoms.
Missed Dose	If a dose is missed, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue your regular dosing schedule. Do not double the dose to make up for the missed one.

Important Safety Notes

This medication is for long-term symptom control and is not to be used for the immediate relief of acute asthma attacks or sudden breathing difficulties. For acute symptoms, use a rapid-acting inhaled rescue medication as directed by your physician. If you experience worsening breathing problems or wheezing after taking Volmax, seek immediate medical attention, as this may be a sign of paradoxical bronchospasm, a potentially life-threatening reaction. Regular follow-up with your healthcare provider is essential to monitor the medication's effectiveness and safety.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Volmax

Evidence for use in Chronic Insomnia

Research evaluating Volmax was studied for chronic insomnia in short-term randomized controlled trials (RCTs). These studies focused on adult patients with chronic insomnia, a condition marked by functional limitations related to sleep. Researchers studied outcomes relevant in trials assessing short-term or episodic symptom patterns, primarily looking at objective measurements from sleep studies (polysomnography) and patient-reported outcomes describing perceived discomfort with their sleep quality.

The findings describe patterns observed in the studies related to changes measured in two main sleep parameters: sleep latency (the time it takes to fall asleep) and total sleep time. Some research highlights changes measured during the study period, indicating patterns related to measurements of sleep latency and total sleep time in the observed populations. However, evidence remains limited and heterogeneous, and the results apply only to the specific populations studied over a defined time interval. Research provides context but not individual predictions.

Long-term outcomes are not well characterized. Data are still emerging, and follow-up durations were limited in the existing studies. There is limited information for long-term outcomes, such as how sleep quality may evolve after the initial treatment period. Comparative evidence is also lacking for how these observed patterns relate to other approaches.

Evidence for use in Major Depressive Disorder (MDD)

Volmax was evaluated in Major Depressive Disorder, a condition presenting with cycles of stability and flare-ups, primarily in adult outpatients. Research examined short-term symptom changes, often using randomized controlled designs. The primary outcomes relevant in evidence describing how symptoms are measured included changes measured in depressive symptom severity, based on standard rating scales.

Studies monitored how symptoms evolved in the observed populations. Data show patterns related to changes measured in scores on standardized depression scales. This research contributes to understanding symptom patterns over the duration of the trial, typically spanning a few weeks.

However, certainty remains low, and the results apply only to the populations studied. Research is ongoing, and there is limited information for long-term outcomes related to managing recurrence over an extended period. Data for certain groups, such as children or older adults with severe, resistant symptoms, remain insufficient, and comparative evidence against other widely used options is lacking.

Evidence for use in Generalized Anxiety Disorder (GAD)

Studies explored Volmax in adult patients with Generalized Anxiety Disorder, a condition where symptoms may vary in intensity. Research focused on episodes where symptoms become more noticeable, often using double-blind, randomized trial designs. Researchers evaluated outcomes related to physiological strain or stress, specifically measuring measurements of anxiety severity using standardized rating scales over defined time intervals.

The research highlights changes measured during the study period related to measurements in anxiety scale scores. Evidence suggests findings describe patterns observed in the studies, suggesting a difference in score changes compared to inactive treatments (placebo) over the initial weeks of observation.

Despite these observations, the evidence quality varies across studies, and findings were mixed in terms of consistency across different trial settings. Follow-up durations were limited, meaning long-term effects are not fully established. There is limited information available on outcomes for patients whose symptoms are particularly severe or who have existing refractory symptoms.

Long-term Studies and Follow-up

This section will summarize the extent of data available regarding the duration of observed effects and what is known or remains unknown about outcomes over extended periods, including any available information on durability of response.

Evidence in Special Populations

This section will detail the findings from studies that specifically evaluated Volmax in certain groups, such as older adults, pediatric populations, or patients with other existing health conditions, where evidence may be limited or distinct.

What is Still Uncertain about Volmax

This concluding section will synthesize the main limitations of the current research, including gaps like small sample sizes, inconsistency across findings, and areas where more investigation is needed to provide a fuller understanding of the research profile. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Volmax (FAQ)

Q: Is Volmax the same as the instant-release version of the medicine?

Volmax is the extended-release (ER) oral tablet form of albuterol sulfate, according to official product information. This means it uses a special sustained-release system to release the medicine slowly over time. This approach differs from the immediate-release (IR) tablet or most inhaled forms, which deliver the active ingredient quickly for rapid onset.

Q: What is the official safety classification of Volmax for use during pregnancy?

Official labeling designates Volmax as Pregnancy Category C. This classification is used when animal studies have suggested a potential risk to the fetus, but there are no adequate studies done in pregnant women. Decisions about its use during pregnancy are based on assessing whether the potential benefits may outweigh the potential risks.

Q: How long does the intended effect of a single dose of Volmax usually last?

Volmax extended-release tablets are formulated to provide a sustained and prolonged therapeutic effect. According to clinical pharmacology data, a single dose of this formulation is designed to last for up to 12 hours.

Q: Is it normal to feel a bit restless when first starting Volmax?

Official information lists nervousness and tremor (shaking) as common side effects of this medicine. Regulatory documents note that these effects, which are characteristic of this type of medication, may gradually subside with continued use. It is important that healthcare professionals are informed of any products being used.

Q: Is Volmax known to interact with herbal tea blends?

According to official drug labels, there are no mandatory interaction rules uniformly documented across major regulatory sources regarding administration with herbal products or herbal tea blends.

Q: What information is available regarding the disposal of unused Volmax?

Official guidelines emphasize the importance of safe disposal. The protocol is to ask a healthcare professional or pharmacist for guidance on properly discarding any unused or expired product. This ensures the medicine is disposed of safely and correctly.

Q: Does Volmax contain any common allergens, like gluten or lactose?

Regulatory documents detailing the composition of the tablet often list anhydrous lactose as an excipient (an inactive ingredient). This indicates the tablet formulation contains lactose.

Q: Are there any specific vitamins or supplements that are known to interact with Volmax?

Regulatory documentation lists known interactions with specific prescription drug classes, such as beta-blockers and diuretics, but does not list specific vitamins or non-xanthine supplements as agents requiring explicit caution or mandatory rules for co-administration.

Q: Can I use Volmax if I have kidney or liver issues?

Official warnings and precautions indicate that the effect of hepatic impairment (liver issues) has not been fully evaluated. For those with renal impairment (kidney issues), data suggests a decline in clearance, and the potential need for caution is suggested by data regarding the medicine’s clearance.

Q: What is generally known about Volmax use in children and teenagers?

The extended-release formulation is not intended for the youngest patients and is formally contraindicated for children 6 years of age and younger. Official documentation provides specific dosage guidance for children aged 6 to 12 years.

Q: What is the general level of evidence supporting the use of Volmax for its approved conditions?

Volmax is formally approved by regulatory agencies for the management of bronchospasm in adult and pediatric patients (aged 6 and older) with reversible obstructive airway disease, such as asthma or COPD. This approval is supported by the Clinical Studies data provided in the regulatory labeling.

Q: Does the time of day I take Volmax matter?

The administration guidelines state that the dosing schedule is typically every 12 hours. Taking the dose at the same time each day is recommended to help maintain a stable level of the medicine in the body.

Q: Can Volmax be taken on an empty stomach?

Official administration guidelines indicate that Volmax may be taken with or without food.

Q: Why does Volmax come in different colors/shapes depending on the dose?

Official documentation from regulatory labels details the physical characteristics of the product under the 'How Supplied' section. This is done so that the different dosage strengths can be easily and accurately identified and distinguished by their unique color, shape, and imprint marks.

Q: Does Volmax have any known impact on blood pressure readings?

The medicine belongs to a class of drugs that can produce clinically significant cardiovascular effects in some people. Regulatory warnings state these effects can include measurable changes in pulse rate and blood pressure.

Q: Can Volmax cause a false positive on any common medical tests?

The active ingredient, salbutamol, is a substance monitored by agencies like the World Anti-Doping Agency (WADA). These agencies set urine concentration thresholds for the substance. The purpose of these thresholds is to distinguish allowed therapeutic use from potential anti-doping rule violations.

How should Volmax be stored and disposed of?

How to Store and Dispose of Volmax

The storage and disposal of Volmax (albuterol extended-release tablets) must align with official regulatory requirements to ensure product integrity and safety.

Storage Conditions

Mandatory storage conditions require the product to be stored at USP Controlled Room Temperature (20 to 25 C) in a closed container. Storage environments must be protected from heat, moisture, and direct light, and the product must be kept from freezing.

Safety and Disposal

All medicine must be stored out of the reach of children.

Patients should not keep outdated medicine or medicine no longer needed. The official disposal protocol requires the patient to ask a healthcare professional for guidance on properly discarding any unused product.

Volmax